Trial Profile
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Protein tyrosine kinase inhibitors
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 20 Nov 2015 New trial record